Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04287985




Registration number
NCT04287985
Ethics application status
Date submitted
10/02/2020
Date registered
27/02/2020
Date last updated
21/11/2024

Titles & IDs
Public title
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy
Secondary ID [1] 0 0
2019-002531-29
Secondary ID [2] 0 0
VIS649-201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Immunoglobulin A Nephropathy 0 0
Glomerular Disease 0 0
IgAN 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dose-Placebo
Treatment: Drugs - Low Dose-VIS649
Treatment: Drugs - Medium Dose-VIS649
Treatment: Drugs - High Dose-VIS649

Placebo comparator: Placebo - Placebo, normal saline (0.9% NaCl) will be administered IV

Experimental: Low Dose - VIS649 - Low dose of VIS649 administered IV

Experimental: Medium Dose - VIS649 - Medium dose of VIS649 administered IV

Experimental: High Dose - VIS649 - High dose of VIS649 administered IV


Treatment: Drugs: Dose-Placebo
Unit Dose Strength - 0.9%.

Treatment: Drugs: Low Dose-VIS649
Dose Level = Low

Treatment: Drugs: Medium Dose-VIS649
Dose Level = Medium

Treatment: Drugs: High Dose-VIS649
Dose Level = High
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Adverse Events Graded by Severity
Timepoint [1] 0 0
Baseline to End of Study (16 months)
Primary outcome [2] 0 0
Changes From Baseline in Clinical Laboratory Tests
Timepoint [2] 0 0
Baseline to End of Study (16 months)
Primary outcome [3] 0 0
Clinically Meaningful Changes From Baseline in Vital Signs
Timepoint [3] 0 0
Baseline to End of Study (16 months)
Primary outcome [4] 0 0
Clinically Significant Physical Examinations
Timepoint [4] 0 0
Baseline to End of Study (16 months)
Primary outcome [5] 0 0
Change From Baseline in uPCR: Month 12
Timepoint [5] 0 0
12 months
Secondary outcome [1] 0 0
Change From Baseline in uPCR: Months 9 and 16
Timepoint [1] 0 0
Baseline to 9 months and 16 months (16 months total)
Secondary outcome [2] 0 0
Change in 24-hour Urine Protein Excretion: Months 12 and 16
Timepoint [2] 0 0
16 months
Secondary outcome [3] 0 0
Participants Achieving a Greater Than or Equal to 30% Decline From Baseline in uPCR at Months 9, 12, and 16
Timepoint [3] 0 0
Baseline to 9,12, and 16 months (16 months total)
Secondary outcome [4] 0 0
Participants in Each Group Achieving Clinical Remission
Timepoint [4] 0 0
Baseline to End of Study (16 months)
Secondary outcome [5] 0 0
Change From Baseline in eGFR at Months 9, 12, and 16
Timepoint [5] 0 0
Baseline to 12 and 16 months
Secondary outcome [6] 0 0
Percent Change From Baseline in Total Serum IgA, IgG, and IgM Concentrations at Months 12 and 16
Timepoint [6] 0 0
Baseline to 12 and 16 months
Secondary outcome [7] 0 0
Mean Serum PK Parameters at Month 0 and Month 11: Cmax
Timepoint [7] 0 0
Months 0 and 11
Secondary outcome [8] 0 0
Median Serum PK Parameters at Month 0 and Month 11: Tmax
Timepoint [8] 0 0
Month 0 and Month 11
Secondary outcome [9] 0 0
Mean Serum PK Parameters at Month 0: AUC0-inf and AUC0-30
Timepoint [9] 0 0
Month 0
Secondary outcome [10] 0 0
Mean Serum PK Parameters at Month 0 and Month 11: t1/2z
Timepoint [10] 0 0
Month 0 and Month 11
Secondary outcome [11] 0 0
Median Serum PK Parameters at Month 0: CL
Timepoint [11] 0 0
Month 0
Secondary outcome [12] 0 0
Mean Serum PK Parameters at Month 0: Vz
Timepoint [12] 0 0
Month 0
Secondary outcome [13] 0 0
Mean Serum PK Parameters at Month 11: AUCt
Timepoint [13] 0 0
Month 11
Secondary outcome [14] 0 0
Mean Serum PK Parameters at Month 11: Vss
Timepoint [14] 0 0
Month 11
Secondary outcome [15] 0 0
Mean Serum PK Parameters at Month 11: CLss
Timepoint [15] 0 0
Month 11
Secondary outcome [16] 0 0
Mean Serum PK Parameters at Month 11: Rac[AUC0-30]
Timepoint [16] 0 0
Month 11

Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:

1. Participant is a male or female = 18 years of age at the time of signing the informed consent.
2. Participant must have biopsy-confirmed IgAN.
3. Participant has medical records showing they have been on stable and maximally tolerated doses of either ACEI or ARB, as per local SOC and applicable guidelines, for at least 3 months preceding screening. Participants should optimally be on at least 50% of the maximum recommended dose of these agents; however, if a participant is on their maximally tolerated dose (and this is < 50% of the maximum recommended dose) and has been on this dose for at least 3 months, they may be enrolled. Participants who are unable to tolerate ACEI/ARB therapy may be eligible for participation in the study if their overall management of IgAN, including BP control, is as per local SOC and applicable guidelines.
4. Participants must have screening uPCR = 0.75 g/g measured from a 24-hour urine or 24-hour urine protein = 1.0 g/d, as measured from 24-hour urine collection. The proteinuria should be assessed when the participant is considered to be in a steady state with no recent heavy exercise, fever, or other potential issues that could impact the result.
5. Participants must have eGFR = 45 mL/min/1.73 m² using the CKD-EPI formula.
6. Participant's serum Ig values must meet specified criteria
7. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose.
8. Participant is willing to adhere to contraceptive requirements.
9. Participant or a legally authorized representative is able and is willing to give voluntary written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Participants are excluded from the study if they meet any of the following criteria:

1. Participant has secondary forms of IgAN as defined by the treating physician.
2. Participant has co-existing CKD, other than IgAN.
3. Participant has evidence of additional pathological findings in the kidney biopsy (eg, diabetic kidney disease, membranous nephropathy, or lupus nephritis). However, hypertensive vascular changes are acceptable.
4. Participant has kidney biopsy MEST or MEST-C score as defined in the protocol.
5. Participant has nephrotic syndrome.
6. Participant has received a solid organ transplant, including kidney.
7. Participant has received bone marrow or hematologic stem cell transplantation.
8. Participant is currently receiving systemic immunosuppression (excluding topical, ophthalmic, per rectum, or inhaled corticosteroids).
9. Participant has received treatment with systemic corticosteroid therapy within 16 weeks of initial screening.
10. Participant has received treatment with a systemic immunosuppressive agents within 16 weeks of initial screening.
11. Participant has any chronic infectious disease.
12. Participant has acute infectious disease at the time of screening.
13. Participant has Type 1 diabetes.
14. Participant has uncontrolled Type 2 diabetes, as evidenced by a screening hemoglobin A1c value > 8%.
15. Participant has uncontrolled BP (> 140 mm Hg systolic or > 90 mm Hg diastolic)
16. Participant has a history of chronic autoimmune neurodegenerative disorder such as multiple sclerosis.
17. Participant has a known allergy or intolerance to any component of the study intervention.
18. Participant is breastfeeding.
19. Participant has poorly compensated or controlled ischemic heart disease or cardiomyopathy, as judged by the Investigator.
20. Participant has chronic obstructive pulmonary disease (COPD) or asthma that has required systemic steroid therapy during the prior year.
21. Participant has known cirrhosis or liver dysfunction, defined as presence of coagulopathy, platelet count < 100,000/µL or alanine aminotransferase > 3× upper limit of normal.
22. Participant has active malignancy or is receiving chemotherapy for malignancy, except for nonmelanoma skin cancers and cervical carcinoma in situ. Participants with prior malignancy who have been documented to be cancer-free for = 5 years may be enrolled.
23. Participant is planning or scheduled to undergo a tonsillectomy. Prior tonsillectomy is acceptable (if greater than 6 months prior to screening).
24. Participant enrolled in another investigational drug or device study within 3 months prior to initial screening.
25. Participant with a pre-existing illness other than those listed above that, in the opinion of the Investigator, would place the participant at increased risk through participation in this study.
26. Participant is unable to comply with study protocol procedures and/or study visit schedules.
27. Participant with known or suspected alcohol or drug abuse that would compromise their safety or study participation of the participant, in the opinion of the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/06/2023
Sample size
Target
Accrual to date
Final
155
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
Visterra Investigational Site - New Lambton Heights
Recruitment hospital [2] 0 0
Visterra Investigational Site - Saint Leonards
Recruitment hospital [3] 0 0
Visterra Investigational Site - Nambour
Recruitment hospital [4] 0 0
Visterra Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [3] 0 0
4560 - Nambour
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Mississippi
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Hong Kong
State/province [16] 0 0
HK
Country [17] 0 0
Hong Kong
State/province [17] 0 0
Hong Kong
Country [18] 0 0
Hong Kong
State/province [18] 0 0
Kowloon
Country [19] 0 0
Hong Kong
State/province [19] 0 0
Tsuen Wan
Country [20] 0 0
India
State/province [20] 0 0
CH
Country [21] 0 0
India
State/province [21] 0 0
DL
Country [22] 0 0
India
State/province [22] 0 0
KA
Country [23] 0 0
India
State/province [23] 0 0
KL
Country [24] 0 0
India
State/province [24] 0 0
TG
Country [25] 0 0
India
State/province [25] 0 0
TN
Country [26] 0 0
India
State/province [26] 0 0
UP
Country [27] 0 0
Japan
State/province [27] 0 0
Aichi
Country [28] 0 0
Japan
State/province [28] 0 0
Nerima Ku
Country [29] 0 0
Japan
State/province [29] 0 0
Tochigi
Country [30] 0 0
Japan
State/province [30] 0 0
Ashikaga-Shi
Country [31] 0 0
Japan
State/province [31] 0 0
Bunkyo-Ku
Country [32] 0 0
Japan
State/province [32] 0 0
Kashihara-shi
Country [33] 0 0
Japan
State/province [33] 0 0
Minato-Ku
Country [34] 0 0
Japan
State/province [34] 0 0
Niigata Shi
Country [35] 0 0
Japan
State/province [35] 0 0
Shinjuku-Ku
Country [36] 0 0
Japan
State/province [36] 0 0
Tsukuba Shi
Country [37] 0 0
Japan
State/province [37] 0 0
Urayasu-Shi
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Dongdaemun-gu
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Gyeonggi-do
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Anyang
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Gangdong
Country [42] 0 0
Korea, Republic of
State/province [42] 0 0
Hwaseong-si
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Seongnam-si
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Seoul
Country [45] 0 0
Malaysia
State/province [45] 0 0
Klang
Country [46] 0 0
Malaysia
State/province [46] 0 0
Kuala Lumpur
Country [47] 0 0
Malaysia
State/province [47] 0 0
Kuantan
Country [48] 0 0
Malaysia
State/province [48] 0 0
Seremban
Country [49] 0 0
Philippines
State/province [49] 0 0
Diliman
Country [50] 0 0
Philippines
State/province [50] 0 0
Quezon City
Country [51] 0 0
Singapore
State/province [51] 0 0
Singapore
Country [52] 0 0
Spain
State/province [52] 0 0
B
Country [53] 0 0
Spain
State/province [53] 0 0
CB
Country [54] 0 0
Spain
State/province [54] 0 0
CO
Country [55] 0 0
Spain
State/province [55] 0 0
SE
Country [56] 0 0
Spain
State/province [56] 0 0
Barcelona
Country [57] 0 0
Spain
State/province [57] 0 0
Madrid
Country [58] 0 0
Spain
State/province [58] 0 0
Sevilla
Country [59] 0 0
Spain
State/province [59] 0 0
Valencia
Country [60] 0 0
Sri Lanka
State/province [60] 0 0
Colombo
Country [61] 0 0
Sri Lanka
State/province [61] 0 0
Kandy
Country [62] 0 0
Sri Lanka
State/province [62] 0 0
Nugegoda
Country [63] 0 0
Taiwan
State/province [63] 0 0
Kaohsiung
Country [64] 0 0
Taiwan
State/province [64] 0 0
Keelung
Country [65] 0 0
Taiwan
State/province [65] 0 0
New Taipei City
Country [66] 0 0
Taiwan
State/province [66] 0 0
Xitun
Country [67] 0 0
Thailand
State/province [67] 0 0
Bangkok
Country [68] 0 0
Thailand
State/province [68] 0 0
Chiang Mai
Country [69] 0 0
Thailand
State/province [69] 0 0
Ratchathewi
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Bradford
Country [71] 0 0
United Kingdom
State/province [71] 0 0
London
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Visterra, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Trial website
https://clinicaltrials.gov/study/NCT04287985
Trial related presentations / publications
Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2.
Public notes

Contacts
Principal investigator
Name 0 0
Asher Schachter, M.D.
Address 0 0
Visterra, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04287985